[Comment] Challenges in the therapeutic management of psoriatic arthritis

In The Lancet Rheumatology, Gabriele De Marco and colleagues1 present their study on the benefit of using methotrexate with golimumab in patients with early psoriatic arthritis. On average, the median time from symptom onset to diagnosis was 10 months. All patients received an intramuscular dose of methylprednisolone 120 mg (or an equivalent intra-articular dose), and methotrexate (increased to 25 mg orally weekly within 28 days) and were randomly assigned to either the golimumab and methotrexate group or the placebo and methotrexate group, stratified by oligoarticular or polyarticular involvement.